Polycyclic Urea Antibacterials Targeting DNA Gyrase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibacterial agents face challenges due to increasing antibiotic resistance, particularly against Gram-positive pathogens like MRSA and Gram-negative bacteria, with existing treatments like vancomycin and quinolones showing toxicity and resistance issues, necessitating the development of new antibiotics with novel mechanisms of action.
Innovation Solution
Development of a new class of compounds targeting DNA gyrase and topoisomerase IV, specifically represented by compounds of formula (XVIII), (XIX), and (XX), which inhibit these enzymes, offering broad-spectrum antibacterial activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vancomycin is used to treat resistant Gram-positive pathogens, then antibacterial effectiveness is improved, but nephrotoxicity and emerging resistance occur
Solution Approach 1:
The patent modifies the core quinolone structure by introducing a cyclopropylidene ring and specific substituents (R1-R6 groups) to create novel compounds with altered pharmacological properties. This structural parameter change aims to achieve potent antibacterial activity against resistant strains while reducing the toxicity and resistance issues associated with conventional antibiotics like vancomycin
Solution Approach 2:
The invention combines elements from different chemical classes - the cyclopropylidene ring system combined with heterocyclic groups (pyrimidine, pyridine, thiazole, etc.) and various substituent patterns - to create composite molecular structures that exhibit enhanced antibacterial activity with improved safety profiles compared to single-class antibiotics
2Adaptability or versatility
If quinolones are used for broad-spectrum antibacterial activity, then coverage of Gram-negative and Gram-positive bacteria is improved, but resistance development and toxic side effects increase
Solution Approach 1:
The patent divides the antibacterial activity into two distinct target components: DNA gyrase inhibition and topoisomerase IV inhibition. By designing compounds that can inhibit both targets, the invention achieves broad-spectrum activity against different bacterial types while potentially reducing resistance development through multi-target action
Solution Approach 2:
The novel quinolone compounds are designed to perform multiple functions: inhibiting DNA gyrase, inhibiting topoisomerase IV, and maintaining broad-spectrum activity. This multi-functionality allows a single compound to address multiple bacterial targets and resistance mechanisms simultaneously
3Reliability
If new antibiotics with novel mechanisms of action are developed, then resistance development is reduced, but manufacturing complexity and development time increase
Solution Approach 1:
The patent employs systematic design of the cyclopropylidene core structure with pre-planned substituent positions (R1-R6) and explores multiple heterocyclic options during the design phase. This preliminary structuring and planning of the molecular framework facilitates more efficient synthesis and development compared to de novo drug discovery
Data Source
AI summary
Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.